Literature DB >> 22228416

Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion.

Gowrie S Balasubramaniam1, Matthew Morris, Arun Gupta, Irene Rebello Mesa, Raj Thuraisingham, Neil Ashman.   

Abstract

BACKGROUND: Blood transfusions are generally avoided for potential renal transplant recipients due to risk of human leukocyte antigen (HLA) allosensitization. Despite the near universal use of erythropoiesis-stimulating agents, there are still occasions when patients require blood transfusions for reasons such as resistance to erythropoiesis-stimulating agents or cardiovascular instability. The risk of allosensitization in renal patients is believed to be lower with leuko-depleted blood. We sought to quantify the risk of blood transfusion per se in male renal patients on the transplant waiting list for their first kidney graft, using sensitive solid phase antibody detection.
METHOD: Cross-sectional survey looking at the prevalence of HLA antibody detected using single antigen Luminex beads in male patients awaiting first renal transplantation.
RESULTS: One hundred sixteen male patients awaiting their first kidney transplant were identified on our waiting list. Seven of the 42 patients (16.7%) who received at least one unit of leuko-depleted blood developed HLA antibody (HLAab). Of the remaining 74 patients without a history of transfusion, 3 (4.1%) were found to have HLAab. All the antibodies identified were directed against class I antigens. A history of blood transfusion gave a relative risk of 4.1 of developing HLAab (P=0.02).
CONCLUSION: Male patients awaiting their first organ transplant had a fourfold increased risk of developing HLA antibody if they had been previously transfused when compared with those who did not have a history of a transfusion. Transfusion even in the postleukodepletion era continues to pose a significant risk of sensitization.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22228416     DOI: 10.1097/TP.0b013e3182419864

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  10 in total

Review 1.  Anaemia management and mortality risk in chronic kidney disease.

Authors:  Walter H Hörl
Journal:  Nat Rev Nephrol       Date:  2013-02-26       Impact factor: 28.314

2.  Red blood cell transfusions are associated with HLA class I but not H-Y alloantibodies in children with sickle cell disease.

Authors:  Robert S Nickel; Jeanne E Hendrickson; Marianne M Yee; Robert A Bray; Howard M Gebel; Leslie S Kean; David B Miklos; John T Horan
Journal:  Br J Haematol       Date:  2015-04-19       Impact factor: 6.998

3.  Sensitization from transfusion in patients awaiting primary kidney transplant.

Authors:  Julie M Yabu; Matthew W Anderson; Deborah Kim; Brian D Bradbury; Calvin D Lou; Jeffrey Petersen; Jerome Rossert; Glenn M Chertow; Dolly B Tyan
Journal:  Nephrol Dial Transplant       Date:  2013-09-05       Impact factor: 5.992

4.  Washing red cells after leucodepletion does not decrease human leukocyte antigen sensitization risk in patients with chronic kidney disease.

Authors:  Antony Aston; Rebecca Cardigan; Saber Bashir; Susan Proffitt; Helen New; Colin Brown; Ri Liesner; Sylvia Hennem; Helen Nulty; Olivia Shaw; Robert Vaughan; Jon Jin Kim; Lesley Rees
Journal:  Pediatr Nephrol       Date:  2014-04-29       Impact factor: 3.714

5.  Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients.

Authors:  Vijay Subramanian; Ankit Bharat; Neeta Vachharajani; Jeffrey Crippin; Surendra Shenoy; Thalachallour Mohanakumar; William C Chapman
Journal:  HPB (Oxford)       Date:  2013-07-22       Impact factor: 3.647

Review 6.  The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation.

Authors:  Stefan O Ciurea; Kai Cao; Marcelo Fernandez-Vina; Piyanuch Kongtim; Monzr Al Malki; Ephraim Fuchs; Leo Luznik; Xiao-Jun Huang; Fabio Ciceri; Franco Locatelli; Franco Aversa; Luca Castagna; Andrea Bacigalupo; Massimo Martelli; Didier Blaise; Rupert Handgretinger; Denis-Claude Roy; Paul O'Donnell; Asad Bashey; Hillard M Lazarus; Karen Ballen; Bipin N Savani; Mohamad Mohty; Arnon Nagler
Journal:  Bone Marrow Transplant       Date:  2018-01-15       Impact factor: 5.483

Review 7.  HLA sensitisation: can it be prevented?

Authors:  Lesley Rees; Jon Jin Kim
Journal:  Pediatr Nephrol       Date:  2014-07-26       Impact factor: 3.714

8.  Early Posttransplant Blood Transfusion and Risk for Worse Graft Outcomes.

Authors:  Reem Daloul; Juarez R Braga; Alejandro Diez; April Logan; Todd Pesavento
Journal:  Kidney Int Rep       Date:  2021-01-16

9.  Chapter 4: Red cell transfusion to treat anemia in CKD.

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2012-08

10.  One good match permits another-why HLA-matched blood transfusion makes sense.

Authors:  Ben C Reynolds; Sally A Johnson; Vaughan Carter; Jonathan P Wallis; Nadeem E Moghal
Journal:  Clin Kidney J       Date:  2013-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.